UK study highlights potential of genetic screening for prostate cancer
Genetic ‘barcoding’ in GP surgeries can identify men at higher risk of prostate cancer, researchers claim
Read More
Tag: Royal Marsden
Immunotherapy extends the life of head and neck cancer patients
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, reports a major new clinical trial.
Read More
Researchers hail “exciting results” in ovarian, lung cancer trial
A chemo/targeted drug combination being trialed by UK researchers has shown promise in patients with advanced ovarian or lung cancer in whom all other treatments have failed.
Read More
Trial first to show immunotherapy benefit in prostate cancer
An international trial led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust has shown that immunotherapy can benefit men with prostate cancer.
Read More
Novartis ties with Royal Marsden to boost cancer care
Cancer patients living in North West and South West London are to benefit from a new Joint Working Project between Novartis and the Royal Marsden Partners Cancer Vanguard that aims to improve quality of care in the region by expanding the role of oncology pharmacists.
Read More
Researchers develop new test to target prostate cancer treatment
UK-based scientists have developed a new three-in-one blood test able to identify the patients with advanced prostate cancer most likely to benefit from PARP inhibitors, with the potential to ‘transform’ treatment of the disease.
Read More
Precision ovarian cancer drug shows early promise
An experimental targeted treatment for ovarian cancer has shown promise in early clinical trials shrinking tumours in half of women with the disease.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
